Sign inJoin waitlistJoin the waitlist

Shirish Gadgeel

Vice Chair for Clinical Research, Department of Hematology and Medical Oncology · Winship Cancer Institute at Emory Midtown

Credentials: · · · ·

History

Department of Hematology and Medical Oncology · Winship Cancer Institute at Emory Midtown
Present
Winship Cancer Institute at Emory Midtown
Present
Emory University School of Medicine
Present

Wayne State University School of Medicine
1996–1999
Internal Medicine
Wayne State University School of Medicine
1994–1996
Laguardia Hospital
1991–1994
Bombay University-IND, MBBS
1985–1989

Research

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2018 · 5,534 citations
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
The Lancet · 2017 · 3,995 citations
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2017 · 2,039 citations

AW
Antoinette Wozniak
32 papers
SO
Sai-Hong I Ou
31 papers
Ross Camidge
24 papers
Alice Shaw
22 papers
Gregory Kalemkerian
21 papers
Lecia Sequist
17 papers
Balazs Halmos
16 papers
GR
Gregory Riely
12 papers · 1 as a fellow
Lyudmila Bazhenova
12 papers
Patricia LoRusso
12 papers
Ayman Soubani
11 papers
David Gandara
11 papers · 1 as a fellow

Grants

Profiling Genetic Alterations in NSCLC in African Americans
National Cancer Institute · R21
PI · $363.7K · Wayne State University
2014–2017

Clinical trials

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Principal investigator · Recruiting · Phase 2
SWOG Cancer Research Network
2024–2028
Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients
Principal investigator · Withdrawn · Phase 2
Shirish M Gadgeel
2021
Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC
Principal investigator · Withdrawn · Phase 2
Shirish Gadgeel
2021–2026
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2016–2027